Suilysin Stimulates the Release of Heparin Binding Protein from Neutrophils and Increases Vascular Permeability in Mice

Shaolong Chen, Wenlong Xie, Kai Wu, Ping Li, Zhiqiang Ren, Lin Li, Yuan Yuan, Chunmao Zhang, Yuling Zheng, Qingyu Lv, Hua Jiang, Yongqiang Jiang, Shaolong Chen, Wenlong Xie, Kai Wu, Ping Li, Zhiqiang Ren, Lin Li, Yuan Yuan, Chunmao Zhang, Yuling Zheng, Qingyu Lv, Hua Jiang, Yongqiang Jiang

Abstract

Most of the deaths that occurred during two large outbreaks of Streptococcus suis infections in 1998 and 2005 in China were caused by streptococcal toxic shock syndrome (STSS), which is characterized by increased vascular permeability. Heparin-binding protein (HBP) is thought to mediate the vascular leakage. The purpose of this study was to investigate the detailed mechanism underlying the release of HBP and the vascular leakage induced by S. suis. Significantly higher serum levels of HBP were detected in Chinese patients with STSS than in patients with meningitis or healthy controls. Suilysin (SLY) is an exotoxin secreted by the highly virulent strain 05ZYH33, and it stimulated the release of HBP from the polymorphonuclear neutrophils and mediated vascular leakage in mice. The release of HBP induced by SLY was caused by a calcium influx-dependent degranulation. Analyses using a pharmacological approach revealed that the release of HBP induced by SLY was related to Toll-like receptor 4, p38 mitogen-activated protein kinase, and the 1-phosphatidylinositol 3-kinase pathway. It was also dependent on a G protein-coupled seven-membrane spanning receptor. The results of this study provide new insights into the vascular leakage in STSS associated with non-Group A streptococci, which could lead to the discovery of potential therapeutic targets for STSS associated with S. suis.

Keywords: Streptococcus suis-associated streptococcal toxic shock syndrome; heparin binding protein; suilysin; vascular permeability.

Figures

FIGURE 1
FIGURE 1
The serum HBP levels were significantly increased in patients with STSS compared with patients without STSS or healthy individuals. The serum HBP levels of healthy individuals (n = 13), patients infected with S. suis presenting meningitis (n = 8), and patients infected with S. suis presenting STSS (n = 6) were determined by ELISA. Data were analyzed by a rank-sum test. ∗∗∗ indicates a significant difference between patients with STSS vs. controls, P = 0.0007.
FIGURE 2
FIGURE 2
05ZYH33 cultures induced the release of HBP in whole blood samples and purified PMN suspension. (A,B) 05ZYH33 cultures significantly induced the release of HBP in human whole blood samples (A) and purified PMN suspensions (B). Whole blood samples or purified PMN suspensions were incubated with 05ZYH33 cultures or THB (control) for 30 min at 37°C. The HBP level in the supernatants was measured by ELISA. The total cell lysate following Triton X-100 treatment was used as the positive control. Data are expressed as the mean ± SD. An unpaired Student’s t-test was used. ∗∗P < 0.01, ∗P < 0.05. (C) Western blotting results of release of HBP from human purified PMN suspensions. rHBP and Triton X-100 were used as positive controls.
FIGURE 3
FIGURE 3
Suilysin secreted from 05ZYH33 induced the release of HBP from PMNs. (A) The release of HBP from whole blood samples was induced by supernatants of 05ZYH33 but not by the bacterial cells. Human whole blood samples were incubated with PBS, THB, 05ZYH33 bacterial cells, or 05ZYH33 supernatants for 30 min at 37°C. The HBP level in the supernatants was measured by ELISA. PBS was considered as the background and THB was used as a negative control. An unpaired Student’s t-test was used for the statistical analysis. (B) Heat treatment of the supernatants significantly reduced the release of HBP from whole blood samples. The supernatants were treated at 100°C for 5 min before being added to whole blood samples. (C) A SDS-PAGE analysis of the elution fraction from anion-exchange and hydrophobic interaction chromatography, which induced the maximal release of HBP. (D) LDH failed to induce the release of HBP from PMNs. The PMNs were incubated with His-LDH or Trix-LDH at 0.1, 1.0, or 10 μg/mL for 30 min at 37°C. (E) Suilysin in the 05ZYH33-supernatant stimulated the PMNs to secret HBP. Human whole blood samples were incubated with PBS, THB, the 05ZYH33-supernatant, the Δsly-supernatant or the CΔsly-supernatant for 30 min at 37°C. (F) Western-blot analysis of the HBP that was released from PMNs incubated with cultures of wild-type 05ZYH33, the Δsly mutant, or purified nSLY. A representative image is presented. ∗∗∗P < 0.001, ∗∗P < 0.01, n.s., not significant. ELISA data are expressed as the mean ± SD of at least four independent experiments.
FIGURE 4
FIGURE 4
Suilysin induced PMN degranulation. (A) Superoxide anion production was not affected by treatment with nSLY or 05ZYH33 supernatants. Purified PMNs were incubated with 0.50, 0.75, or 1.0 μg/mL nSLY, the 05ZYH33-supernatant, or HBSS for 30 min at 37°C. Following treatment, the cells were stimulated with 200 ng/ml PMA in the presence of 0.1 mM cytochrome C. The superoxide anion production was determined by measuring the absorbance at 550 nm. Data are expressed as the mean ± SD of three independent experiments. (B) Western blot analysis of release of HBP from PMNs that were treated as described for the measurement of superoxide anion production. Thirty microliters of each sample was loaded in each lane. A representative image is presented. (C,D) Scanning electron microscopy images of purified PMNs that were pre-incubated with HBSS (C) or 1 μg/mL nSLY (D). Red arrows indicate excessive membrane ruffles. Representative images are presented. The scale bar represents 5 μm. (E–G). Levels of membrane-associated marker proteins for PMN degranulation, CD63 (E), CD11b (F), and CD66b (G) were increased by 1 μg/mL rSLY. PMNs were stimulated with HBSS as a negative control (—), SLY-isotype (—), rSLY (—), or rFhb (—) and analyzed by flow cytometry. (H,I) Levels of granule marker proteins for PMN degranulation, elastase (H) and lactoferrin (I) were increased by 1 μg/mL nSLY or the 05ZYH33 supernatant. ∗∗∗P < 0.001, ∗∗P < 0.01. ELISA data are presented as the mean ± SD of at least three independent experiments.
FIGURE 5
FIGURE 5
SLY induced a Ca2+ influx and the release of HBP was dependent on the Ca2+ influx. (A) The SLY-induced release of HBP from human whole blood samples was abolished by EGTA. PMNs were pre-incubated with EGTA (10 mM) for 1 h at 37°C. ∗∗∗P < 0.001. (B) SLY induced a Ca2+ influx. Positive control fMLP, negative control LPS, nSLY, nSLY with pre-incubation of EGTA or with Ca2+-free HBSS, rSLY, non-hemolytic SLY mutant P353V was added to a confocal small dish containing purified PMNs loaded with the fluorescent Ca2+ indicator Fluo-3/AM at the indicated time (60 s, arrow), and Ca2+ mobilization was monitored by real-time fluorescence microscopy for 250 s. (C) SLY in the 05ZYH33-supernatant stimulated a Ca2+ influx. The positive control was fMLP, the negative control was LPS, and the 05ZYH33-supernatant, THB, the Δsly-supernatant, the 05ZYH33-supernatant with pre-incubation of EGTA were used as stimulants. The fluorescence intensity of at least eight cells in one vision was measured and the mean increase intensity is presented.
FIGURE 6
FIGURE 6
Receptor and signal molecule were involved in the Suilysin induced release of HBP. (A,B) The release of HBP was blocked by the TLR4-specific inhibitor CLI-095 (3 μM; A) and the TLR4-non-specific inhibitor OxPAPC (30 μg/mL; B). (C,D) The release of HBP was not affected by the PLC and PLA2 inhibitor U73122 (10 μM; C) and the ERK1/2 inhibitor PD98095 (20 μM; D). (E–H) The release of HBP was blocked by the p38 MAPK inhibitor SB203580 (10 μM; E), the PI3K inhibitor Wortmannin (1.0 μM; F), the GPRP inhibitor PTX (0.15 μg/mL; G) but not by the RTK inhibitor Genistein (100 μM; H). The PMNs were pre-treated with or without the inhibitors at 37°C for 1 h (PTX for 3h and CLI-095 for 6 h) before a 30 min incubation with the stimulants at 37°C. The HBP level was measured by ELISA. The HBP level relative to the total amount of HBP in the cell lysate from treatment with Triton X-100 was calculated. The data are expressed as the mean ± SD of at least four independent experiments. ∗∗∗P < 0.001. n.s., not significant.
FIGURE 7
FIGURE 7
Suilysin increased the vascular leakage in C57BL mice. (A,B) SLY increased the vascular leakage in mice. C57BL/6J mice were intradermally injected with THB, the 05ZYH33-supernatant, the Δsly-supernatant, or the CΔsly-supernatant. Four hours later, Evans blue dye (2.5%, 100 μL) was injected via the tail vein. After 30 min, photographs of the skin area containing the extravasated protein-bound dye were taken, and the dye was extracted from the skin using formamide. Dye concentrations were measured at 630 nm using a spectrophotometer. (C,D) The 05ZYH33 supernatant did not induce vascular leakage in Tlr4 knockout mice. TLR4+/+ and TLR4-/- were treated in the similar ways as in (A,B). ∗∗∗P < 0.001, ∗∗P < 0.01, n.s., not significant.

References

    1. Allen A. G., Bolitho S., Lindsay H., Khan S., Bryant C., Norton P., et al. (2001). Generation and characterization of a defined mutant of Streptococcus suis lacking suilysin. Infect. Immun. 69 2732–2735. 10.1128/IAI.69.4.2732-2735.2001
    1. Bi L., Pian Y., Chen S., Ren Z., Liu P., Lv Q., et al. (2015). Toll-like receptor 4 confers inflammatory response to suilysin. Front. Microbiol. 6:644 10.3389/fmicb.2015.00644
    1. Borregaard N., Cowland J. B. (1997). Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89 3503–3521.
    1. Brosnahan A. J., Schlievert P. M. (2011). Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome. FEBS J. 278 4649–4667. 10.1111/j.1742-4658.2011.08151.x
    1. Brown E. J. (2004). The molecular basis of streptococcal toxic shock syndrome. N. Engl. J. Med. 350 2093–2094. 10.1056/NEJMcibr040657
    1. Chew M. S., Linder A., Santen S., Ersson A., Herwald H., Thorlacius H. (2012). Increased plasma levels of heparin-binding protein in patients with shock: a prospective, cohort study. Inflamm. Res. 61 375–379. 10.1007/s00011-011-0422-6
    1. Di Gennaro A., Kenne E., Wan M., Soehnlein O., Lindbom L., Haeggstrom J. Z. (2009). Leukotriene B4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin). FASEB J. 23 1750–1757. 10.1096/fj.08-121277
    1. Du H., Huang W., Xie H., Ye C., Jing H., Ren Z., et al. (2013). The genetically modified suilysin, rSLY(P353L), provides a candidate vaccine that suppresses proinflammatory response and reduces fatality following infection with Streptococcus suis. Vaccine 31 4209–4215. 10.1016/j.vaccine.2013.07.004
    1. Du H., Xu L., Wang X., Li X., Ye C., Xu J. (2009). [Biological profiles of recombinant suilysin]. Wei Sheng Wu Xue Bao 49 792–798.
    1. Edens H. A., Parkos C. A. (2003). Neutrophil transendothelial migration and alteration in vascular permeability: focus on neutrophil-derived azurocidin. Curr. Opin. Hematol. 10 25–30. 10.1097/00062752-200301000-00005
    1. Ekelund K., Skinhoj P., Madsen J., Konradsen H. B. (2005). Invasive group A, B, C and G streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects. Clin. Microbiol. Infect. 11 569–576. 10.1111/j.1469-0691.2005.01169.x
    1. Gautam N., Hedqvist P., Lindbom L. (1998). Kinetics of leukocyte-induced changes in endothelial barrier function. Br. J. Pharmacol. 125 1109–1114. 10.1038/sj.bjp.0702186
    1. Gautam N., Herwald H., Hedqvist P., Lindbom L. (2000). Signaling via beta(2) integrins triggers neutrophil-dependent alteration in endothelial barrier function. J. Exp. Med. 191 1829–1839. 10.1084/jem.191.11.1829
    1. Gautam N., Olofsson A. M., Herwald H., Iversen L. F., Lundgren-Akerlund E., Hedqvist P., et al. (2001). Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat. Med. 7 1123–1127. 10.1038/nm1001-1123
    1. Gomez E., Kennedy C. C., Gottschalk M., Cunningham S. A., Patel R., Virk A. (2014). Streptococcus suis-related prosthetic joint infection and streptococcal toxic shock-like syndrome in a pig farmer in the United States. J. Clin. Microbiol 52 2254–2258. 10.1128/JCM.02934-13
    1. Gottschalk M., Lebrun A., Wisselink H., Dubreuil J. D., Smith H., Vecht U. (1998). Production of virulence-related proteins by Canadian strains of Streptococcus suis capsular type 2. Can. J. Vet. Res. 62 75–79.
    1. Gottschalk M., Xu J., Calzas C., Segura M. (2010). Streptococcus suis: a new emerging or an old neglected zoonotic pathogen? Future Microbiol. 5 371–391. 10.2217/fmb.10.2
    1. Hashikawa S., Iinuma Y., Furushita M., Ohkura T., Nada T., Torii K., et al. (2004). Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J. Clin. Microbiol. 42 186–192. 10.1128/JCM.42.1.186-192.2004
    1. He Z., Pian Y., Ren Z., Bi L., Yuan Y., Zheng Y., et al. (2014). Increased production of suilysin contributes to invasive infection of the Streptococcus suis strain 05ZYH33. Mol. Med. Rep. 10 2819–2826. 10.3892/mmr.2014.2586
    1. Herwald H., Cramer H., Morgelin M., Russell W., Sollenberg U., Norrby-Teglund A., et al. (2004). M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116 367–379. 10.1016/S0092-8674(04)00057-1
    1. Hu X., Zhu F., Wang H., Chen S., Wang G., Sun J., et al. (2000). [Studies on human streptococcal infectious syndrome caused by infected pigs]. Zhonghua Yu Fang Yi Xue Za Zhi 34 150–152.
    1. Jacobs A. A., Loeffen P. L., van den Berg A. J., Storm P. K. (1994). Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infect. Immun. 62 1742–1748.
    1. Jacobs A. A., van den Berg A. J., Loeffen P. L. (1996). Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. Vet. Rec. 139 225–228. 10.1136/vr.139.10.225
    1. Johansson J., Lindbom L., Herwald H., Sjoberg F. (2009). Neutrophil-derived heparin binding protein–a mediator of increased vascular permeability after burns? Burns 35 1185–1187. 10.1016/j.burns.2009.02.021
    1. Lacy P. (2006). Mechanisms of degranulation in neutrophils. Allergy Asthma Clin. Immunol. 2 98–108. 10.1186/1710-1492-2-3-98
    1. Lacy P., Eitzen G. (2008). Control of granule exocytosis in neutrophils. Front. Biosci. 13 5559–5570. 10.2741/3099
    1. Lee T. D., Gonzalez M. L., Kumar P., Grammas P., Pereira H. A. (2003). CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers. Microvasc. Res. 66 38–48. 10.1016/S0026-2862(03)00010-4
    1. Linder A., Akesson P., Inghammar M., Treutiger C. J., Linner A., Sunden-Cullberg J. (2012). Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. Crit. Care 16 R90. 10.1186/cc11353
    1. Linder A., Christensson B., Herwald H., Bjorck L., Akesson P. (2009). Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin. Infect. Dis. 49 1044–1050. 10.1086/605563
    1. Liu S., Tobias R., McClure S., Styba G., Shi Q., Jackowski G. (1997). Removal of endotoxin from recombinant protein preparations. Clin. Biochem. 30 455–463. 10.1016/S0009-9120(97)00049-0
    1. Low D. E. (2013). Toxic shock syndrome: major advances in pathogenesis, but not treatment. Crit. Care Clin. 29 651–675. 10.1016/j.ccc.2013.03.012
    1. Lu H. Z., Weng X. H., Zhu B., Li H., Yin Y. K., Zhang Y. X., et al. (2003). Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis. J. Clin. Microbiol. 41 3051–3055. 10.1128/JCM.41.7.3051-3055.2003
    1. Lun S., Perez-Casal J., Connor W., Willson P. J. (2003). Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2. Microb. Pathog. 34 27–37. 10.1016/S0882-4010(02)00192-4
    1. Lun Z. R., Wang Q. P., Chen X. G., Li A. X., Zhu X. Q. (2007). Streptococcus suis: an emerging zoonotic pathogen. Lancet Infect. Dis. 7 201–209. 10.1016/S1473-3099(07)70001-4
    1. Lv Q., Hao H., Bi L., Zheng Y., Zhou X., Jiang Y. (2014). Suilysin remodels the cytoskeletons of human brain microvascular endothelial cells by activating RhoA and Rac1 GTPase. Protein Cell 5 261–264. 10.1007/s13238-014-0037-0
    1. Malley R., Henneke P., Morse S. C., Cieslewicz M. J., Lipsitch M., Thompson C. M., et al. (2003). Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. U.S.A. 100 1966–1971. 10.1073/pnas.0435928100
    1. Nilsson M., Sorensen O. E., Morgelin M., Weineisen M., Sjobring U., Herwald H. (2006). Activation of human polymorphonuclear neutrophils by streptolysin O from Streptococcus pyogenes leads to the release of proinflammatory mediators. Thromb. Haemost. 95 982–990.
    1. O’Flaherty J. T., Rossi A. G., Jacobson D. P., Redman J. F. (1991). Roles of Ca2+ in human neutrophil responses to receptor agonists. Biochem. J. 277 705–711. 10.1042/bj2770705
    1. Pahlman L. I., Morgelin M., Eckert J., Johansson L., Russell W., Riesbeck K., et al. (2006). Streptococcal M protein: a multipotent and powerful inducer of inflammation. J. Immunol. 177 1221–1228. 10.4049/jimmunol.177.2.1221
    1. Park J. M., Ng V. H., Maeda S., Rest R. F., Karin M. (2004). Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J. Exp. Med. 200 1647–1655. 10.1084/jem.20041215
    1. Perch B., Kristjansen P., Skadhauge K. (1968). Group R streptococci pathogenic for man. Two cases of meningitis and one fatal case of sepsis. Acta Pathol. Microbiol. Scand. 74 69–76. 10.1111/j.1699-0463.1968.tb03456.x
    1. Pereira H. A., Shafer W. M., Pohl J., Martin L. E., Spitznagel J. K. (1990). CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity. J. Clin. Invest. 85 1468–1476. 10.1172/JCI114593
    1. Ren Z. Q., Zheng Y. L., Gan S. Z., Lv Q. Y., Hao H. J., Jiang Y. Q., et al. (2012). [Construction and activities of suilysin mutants]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28 580–582.
    1. Segura M. (2009). Streptococcus suis: an emerging human threat. J. Infect. Dis. 199 4–6. 10.1086/594371
    1. Segura M., Stankova J., Gottschalk M. (1999). Heat-killed Streptococcus suis capsular type 2 strains stimulate tumor necrosis factor alpha and interleukin-6 production by murine macrophages. Infect. Immun. 67 4646–4654.
    1. Segura M., Vanier G., Al-Numani D., Lacouture S., Olivier M., Gottschalk M. (2006). Proinflammatory cytokine and chemokine modulation by Streptococcus suis in a whole-blood culture system. FEMS Immunol. Med. Microbiol. 47 92–106. 10.1111/j.1574-695X.2006.00067.x
    1. Soehnlein O., Xie X., Ulbrich H., Kenne E., Rotzius P., Flodgaard H., et al. (2005). Neutrophil-derived heparin-binding protein (HBP/CAP37) deposited on endothelium enhances monocyte arrest under flow conditions. J. Immunol. 174 6399–6405. 10.4049/jimmunol.174.10.6399
    1. Srivastava A., Henneke P., Visintin A., Morse S. C., Martin V., Watkins C., et al. (2005). The apoptotic response to pneumolysin is toll-like receptor 4 dependent and protects against pneumococcal disease. Infect. Immun. 73 6479–6487. 10.1128/IAI.73.10.6479-6487.2005
    1. Staats J. J., Feder I., Okwumabua O., Chengappa M. M. (1997). Streptococcus suis: past and present. Vet. Res. Commun. 21 381–407. 10.1023/A:1005870317757
    1. Tang J., Wang C., Feng Y., Yang W., Song H., Chen Z., et al. (2006). Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Med. 3:e151 10.1371/journal.pmed.0030151
    1. Tapper H., Karlsson A., Morgelin M., Flodgaard H., Herwald H. (2002). Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. Blood 99 1785–1793. 10.1182/blood.V99.5.1785
    1. Tramontana A. R., Graham M., Sinickas V., Bak N. (2008). An Australian case of Streptococcus suis toxic shock syndrome associated with occupational exposure to animal carcasses. Med. J. Aust. 188 538–539.
    1. Wertheim H. F., Nghia H. D., Taylor W., Schultsz C. (2009). Streptococcus suis: an emerging human pathogen. Clin. Infect. Dis. 48 617–625. 10.1086/596763
    1. Xu L., Huang B., Du H., Zhang X. C., Xu J., Li X., et al. (2010). Crystal structure of cytotoxin protein suilysin from Streptococcus suis. Protein Cell 1 96–105. 10.1007/s13238-010-0012-3
    1. Ye C., Zheng H., Zhang J., Jing H., Wang L., Xiong Y., et al. (2009). Clinical, experimental, and genomic differences between intermediately pathogenic, highly pathogenic, and epidemic Streptococcus suis. J. Infect. Dis. 199 97–107. 10.1086/594370
    1. Ye C., Zhu X., Jing H., Du H., Segura M., Zheng H., et al. (2006). Streptococcus suis sequence type 7 outbreak, Sichuan, China. Emerg. Infect. Dis. 12 1203–1208. 10.3201/eid1708.060232
    1. Yu H., Jing H., Chen Z., Zheng H., Zhu X., Wang H., et al. (2006). Human Streptococcus suis outbreak, Sichuan, China. Emerg. Infect. Dis. 12 914–920. 10.3201/eid1206.051194

Source: PubMed

3
Tilaa